Tirdzniecība Regeneron Pharmaceuticals, Inc. - REGN CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Tirdzniecības Nosacījumi
| Starpība | 4.75 | ||||||||
|
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.030779% | ||||||||
|
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | -0.013666% | ||||||||
| Nakts laika nodeva | 22:00 (UTC) | ||||||||
| Min. tirgotais daudzums | 1 | ||||||||
| Valūta | USD | ||||||||
| Drošības rezerve | 20% | ||||||||
| Fondu birža | United States of America | ||||||||
| Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Regeneron Pharmaceuticals Inc ESG Risk Ratings
High Medium Low Negligible
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Galvenie Statistikas Dati
| Iepriekš. aizvērt* | 750.43 |
| Atvērt* | 760.24 |
| Izmaiņas par 1 gadu* | 22.29% |
| Dienas Diapazons* | 760.24 - 786.86 |
| 52 ned Diapazons | 538.01-779.00 |
| Vidējais apjoms (10 dienas) | 623.79K |
| Vidējais apjoms (3 mēneši) | 13.02M |
| Tirgus Kapitalizācija | 81.81B |
| Cenas/Peļņas Attiecība | 15.85 |
| Izvietotās Akcijas | 108.90M |
| Ieņēmumi | 13.71B |
| EPS | 47.40 |
| Dividende (Ienesīgums %) | N/A |
| Beta | 0.20 |
| Nākamās Peļņas Datums | May 2, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
|---|---|---|---|---|---|---|
| Feb 3, 2023 | 781.51 | 25.98 | 3.44% | 755.53 | 789.52 | 752.91 |
| Feb 2, 2023 | 750.43 | 10.27 | 1.39% | 740.16 | 758.10 | 735.76 |
| Feb 1, 2023 | 757.17 | 4.26 | 0.57% | 752.91 | 761.95 | 741.22 |
| Jan 31, 2023 | 757.61 | 18.68 | 2.53% | 738.93 | 758.62 | 738.93 |
| Jan 30, 2023 | 736.29 | -6.26 | -0.84% | 742.55 | 746.95 | 730.67 |
| Jan 27, 2023 | 742.43 | 0.57 | 0.08% | 741.86 | 747.94 | 738.87 |
| Jan 26, 2023 | 741.41 | 1.29 | 0.17% | 740.12 | 745.24 | 730.89 |
| Jan 25, 2023 | 740.89 | 21.04 | 2.92% | 719.85 | 743.70 | 719.85 |
| Jan 24, 2023 | 726.47 | -4.62 | -0.63% | 731.09 | 731.09 | 720.83 |
| Jan 23, 2023 | 729.10 | 13.61 | 1.90% | 715.49 | 732.54 | 710.18 |
| Jan 20, 2023 | 720.89 | 0.54 | 0.07% | 720.35 | 725.08 | 712.07 |
| Jan 19, 2023 | 715.30 | -5.20 | -0.72% | 720.50 | 728.74 | 710.98 |
| Jan 18, 2023 | 724.16 | 4.22 | 0.59% | 719.94 | 728.95 | 719.85 |
| Jan 17, 2023 | 727.63 | 9.94 | 1.38% | 717.69 | 731.09 | 709.88 |
| Jan 13, 2023 | 721.17 | 8.76 | 1.23% | 712.41 | 724.20 | 705.29 |
| Jan 12, 2023 | 714.10 | 11.57 | 1.65% | 702.53 | 715.30 | 695.40 |
| Jan 11, 2023 | 709.10 | 10.75 | 1.54% | 698.35 | 711.03 | 688.80 |
| Jan 10, 2023 | 698.22 | 31.22 | 4.68% | 667.00 | 706.58 | 666.99 |
| Jan 9, 2023 | 680.01 | -11.36 | -1.64% | 691.37 | 707.57 | 663.43 |
| Jan 6, 2023 | 736.23 | 12.23 | 1.69% | 724.00 | 747.67 | 715.20 |
Regeneron Pharmaceuticals, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Ikgadējs
- Ceturkšņa
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Kopējie ienākumi | 4860.43 | 5872.23 | 6710.8 | 7863.4 | 8497.1 | 16071.7 |
| Ienākumi | 4860.43 | 5872.23 | 6710.8 | 7863.4 | 8497.1 | 16071.7 |
| Cost of Revenue, Total | 299.694 | 397.061 | 434.1 | 782.2 | 1119.9 | 2437.5 |
| Bruto Peļņa | 4560.73 | 5475.17 | 6276.7 | 7081.2 | 7377.2 | 13634.2 |
| Kopējie Darbības Izdevumi | 3529.69 | 3792.64 | 4176.4 | 5653.6 | 4920.5 | 7124.9 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 1177.7 | 1320.43 | 1556.2 | 1834.8 | 1346 | 1824.9 |
| Pētniecība un Attīstība | 2052.29 | 2075.14 | 2186.1 | 3036.6 | 2735 | 2908.1 |
| Darbības Izdevumi | 1330.74 | 2079.59 | 2534.4 | 2209.8 | 3576.6 | 8946.8 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -7.195 | -25.119 | 13.7 | 88.1 | 139.1 | 328.8 |
| Citi, Neto | 6.269 | 24.039 | 5.4 | 131.2 | 94.7 | 50.2 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | 1329.81 | 2078.51 | 2553.5 | 2429.1 | 3810.4 | 9325.8 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | 895.522 | 1524.71 | 2376.4 | 2115.8 | 3513.2 | 8075.3 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | 895.522 | 1524.71 | 2376.4 | 2115.8 | 3513.2 | 8075.3 |
| Neto Ienākumi | 895.522 | 1198.51 | 2444.4 | 2115.8 | 3513.2 | 8075.3 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | 895.522 | 1524.71 | 2376.4 | 2115.8 | 3513.2 | 8075.3 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | 895.522 | 1198.51 | 2444.4 | 2115.8 | 3513.2 | 8075.3 |
| Atšķaidīšanas Iestāstīšana | 0.5039 | 0 | ||||
| Atšķaidītie Neto Ienākumi | 896.026 | 1198.51 | 2444.4 | 2115.8 | 3513.2 | 8075.3 |
| Atšķaidītie Ienākumi par Akcijām | 116.367 | 115.954 | 114.8 | 114.6 | 115.1 | 112.2 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | 7.7 | 13.1493 | 20.7003 | 18.4625 | 30.523 | 71.9724 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||||
| Atšķaidītā Normalizētā Peļņa par Akciju | 7.7 | 13.1493 | 20.7003 | 18.4625 | 30.523 | 71.9724 |
| Ārkārtas Posteņi Kopā | -326.2 | 68 | ||||
| Other Operating Expenses, Total | -280.4 | -45.6 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 2528.7 | 5138.5 | 3452.8 | 4951.7 | 2965.1 |
| Ienākumi | 2528.7 | 5138.5 | 3452.8 | 4951.7 | 2965.1 |
| Cost of Revenue, Total | 308 | 693.7 | 453.2 | 982.6 | 404.9 |
| Bruto Peļņa | 2220.7 | 4444.8 | 2999.6 | 3969.1 | 2560.2 |
| Kopējie Darbības Izdevumi | 1416 | 1791.3 | 1605.6 | 2312 | 1706.6 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 405.6 | 414.7 | 445 | 559.6 | 450 |
| Pētniecība un Attīstība | 742.9 | 714.2 | 665.4 | 785.6 | 843.8 |
| Other Operating Expenses, Total | -40.5 | -31.3 | 42 | -15.8 | -20.2 |
| Darbības Izdevumi | 1112.7 | 3347.2 | 1847.2 | 2639.7 | 1258.5 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | 129.3 | 394.6 | -43.3 | -151.8 | -224.8 |
| Citi, Neto | 11 | 11 | 12.7 | 15.5 | 27.4 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | 1253 | 3752.8 | 1816.6 | 2503.4 | 1061.1 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | 1115.2 | 3098.9 | 1632.2 | 2229 | 973.5 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | 1115.2 | 3098.9 | 1632.2 | 2229 | 973.5 |
| Neto Ienākumi | 1115.2 | 3098.9 | 1632.2 | 2229 | 973.5 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | 1115.2 | 3098.9 | 1632.2 | 2229 | 973.5 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | 1115.2 | 3098.9 | 1632.2 | 2229 | 973.5 |
| Atšķaidītie Neto Ienākumi | 1115.2 | 3098.9 | 1632.2 | 2229 | 973.5 |
| Atšķaidītie Ienākumi par Akcijām | 110.5 | 110.8 | 113.9 | 113.4 | 113.1 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | 10.0923 | 27.9684 | 14.3301 | 19.6561 | 8.60743 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Atšķaidītā Normalizētā Peļņa par Akciju | 10.0923 | 27.9684 | 14.3301 | 19.6561 | 8.85588 |
| Neparedzēti Izdevumi (Ienākumi) | 28.1 |
- Ikgadējs
- Ceturkšņa
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 3180.19 | 4335.03 | 6447.6 | 7689.1 | 9779.1 | 14014.9 |
| Nauda un Īstermiņa Ieguldījumi | 1038.68 | 1409.58 | 2809.9 | 3214.3 | 3587 | 5694.7 |
| Nauda un Ekvivalenti | 535.203 | 812.733 | 1467.7 | 1617.8 | 2193.7 | 2885.6 |
| Īstermiņa Ieguldījumi | 503.481 | 596.847 | 1342.2 | 1596.5 | 1393.3 | 2809.1 |
| Debitoru Parādu Kopsumma, Neto | 1611.62 | 1974.34 | 2243.2 | 2672.2 | 4114.7 | 6036.5 |
| Accounts Receivable - Trade, Net | 1611.62 | 1974.34 | 2243.2 | 2672.2 | 4114.7 | 6036.5 |
| Total Inventory | 307.922 | 513.878 | 822.3 | 1014.6 | 1485.7 | 1502.8 |
| Prepaid Expenses | 130.528 | 224.972 | 243.3 | 387.1 | 160.8 | 332.4 |
| Other Current Assets, Total | 91.434 | 212.26 | 328.9 | 400.9 | 430.9 | 448.5 |
| Total Assets | 6973.47 | 8764.29 | 11734.5 | 14805.2 | 17163.3 | 25434.8 |
| Property/Plant/Equipment, Total - Net | 2083.42 | 2358.6 | 2575.8 | 2890.4 | 3221.6 | 3482.2 |
| Property/Plant/Equipment, Total - Gross | 2508.93 | 2924.9 | 3304.5 | 3812.8 | 4352.7 | 4880.3 |
| Accumulated Depreciation, Total | -425.504 | -566.294 | -728.7 | -922.4 | -1131.1 | -1398.1 |
| Long Term Investments | 864.26 | 1486.49 | 1800.5 | 3312.4 | 3194.8 | 6878 |
| Other Long Term Assets, Total | 845.597 | 584.157 | 910.6 | 913.3 | 967.8 | 1059.7 |
| Total Current Liabilities | 1241.49 | 1135.48 | 1442.8 | 2096.6 | 2697.4 | 3932.5 |
| Accounts Payable | 134.984 | 178.183 | 218.2 | 418.1 | 475.5 | 564 |
| Accrued Expenses | 508.336 | 636.668 | 751.3 | 1037.4 | 1502.3 | 1880.5 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 127.274 | 0 | 719.7 | |||
| Other Current Liabilities, Total | 470.901 | 320.632 | 473.3 | 641.1 | 719.6 | 768.3 |
| Total Liabilities | 2524.22 | 2620.21 | 2977.2 | 3715.5 | 6138 | 6666 |
| Total Long Term Debt | 351.569 | 703.453 | 708.5 | 713.9 | 2695.7 | 1980 |
| Capital Lease Obligations | 351.569 | 703.453 | 708.5 | 713.9 | 717.2 | 0 |
| Other Liabilities, Total | 931.157 | 781.272 | 825.9 | 905 | 744.9 | 753.5 |
| Total Equity | 4449.25 | 6144.08 | 8757.3 | 11089.7 | 11025.3 | 18768.8 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.11 | 0.112 | 0.1 | 0.1 | 0.1 | 0.1 |
| Additional Paid-In Capital | 3029.99 | 3512.83 | 3911.6 | 4428.6 | 6716.2 | 8087.5 |
| Retained Earnings (Accumulated Deficit) | 1748.22 | 2946.73 | 5254.3 | 7379.8 | 10893 | 18968.3 |
| Treasury Stock - Common | -316.24 | -316.24 | -396.4 | -739.9 | -6613.3 | -8260.9 |
| Other Equity, Total | -12.84 | 0.64 | -12.3 | 21.1 | 29.3 | -26.2 |
| Total Liabilities & Shareholders’ Equity | 6973.47 | 8764.29 | 11734.5 | 14805.2 | 17163.3 | 25434.8 |
| Total Common Shares Outstanding | 106.008 | 107.625 | 109.006 | 110.277 | 106.951 | 108.675 |
| Long Term Debt | 1978.5 | 1980 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 10055.1 | 13337.6 | 13775.4 | 14014.9 | 14306 |
| Nauda un Īstermiņa Ieguldījumi | 3503.8 | 3910.8 | 5787.6 | 5694.7 | 7050.6 |
| Nauda un Ekvivalenti | 1437.9 | 2072.2 | 3432.4 | 2885.6 | 3345.7 |
| Īstermiņa Ieguldījumi | 2065.9 | 1838.6 | 2355.2 | 2809.1 | 3704.9 |
| Debitoru Parādu Kopsumma, Neto | 4173 | 6998.6 | 5452 | 6036.5 | 4839 |
| Accounts Receivable - Trade, Net | 4173 | 6998.6 | 5452 | 6036.5 | 4839 |
| Total Inventory | 1665.3 | 1448.9 | 1550.1 | 1502.8 | 1465.7 |
| Prepaid Expenses | 213.6 | 444.3 | 482 | 332.4 | 424.9 |
| Other Current Assets, Total | 499.4 | 535 | 503.7 | 448.5 | 525.8 |
| Total Assets | 17772.2 | 21485.9 | 23671.5 | 25434.8 | 26348.7 |
| Property/Plant/Equipment, Total - Net | 3262.6 | 3358.5 | 3395.7 | 3482.2 | 3556.4 |
| Long Term Investments | 3583.7 | 3940.3 | 5671.3 | 6878 | 7130.7 |
| Other Long Term Assets, Total | 870.8 | 849.5 | 829.1 | 1059.7 | 1355.6 |
| Total Current Liabilities | 3217.8 | 3732.4 | 3714.8 | 3932.5 | 3007.6 |
| Accounts Payable | 542.9 | 476 | 427 | 564 | 470.3 |
| Accrued Expenses | 1492.2 | 2018 | 2061 | 2206.8 | 2046 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 717.8 | 718.4 | 719 | 719.7 | 0 |
| Other Current Liabilities, Total | 464.9 | 520 | 507.8 | 442 | 491.3 |
| Total Liabilities | 5795.2 | 6358.6 | 6413.5 | 6666 | 6434 |
| Total Long Term Debt | 1978.9 | 1979.2 | 1979.6 | 1980 | 2700.4 |
| Long Term Debt | 1978.9 | 1979.2 | 1979.6 | 1980 | 1980.4 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 720 |
| Other Liabilities, Total | 598.5 | 647 | 719.1 | 753.5 | 726 |
| Total Equity | 11977 | 15127.3 | 17258 | 18768.8 | 19914.7 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Additional Paid-In Capital | 6887.8 | 7225.8 | 7919.3 | 8087.5 | 8754.1 |
| Retained Earnings (Accumulated Deficit) | 12008.2 | 15107.1 | 16739.3 | 18968.3 | 19941.8 |
| Treasury Stock - Common | -6935.3 | -7221.4 | -7410.2 | -8260.9 | -8611.2 |
| Other Equity, Total | 16.2 | 15.7 | 9.5 | -26.2 | -170.1 |
| Total Liabilities & Shareholders’ Equity | 17772.2 | 21485.9 | 23671.5 | 25434.8 | 26348.7 |
| Total Common Shares Outstanding | 106.644 | 106.72 | 108.527 | 108.675 | 109.507 |
- Ikgadējs
- Ceturkšņa
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Neto ienākumi/Sākuma Līnija | 895.5 | 1198.51 | 2444.4 | 2115.8 | 3513.2 | 8075.3 |
| Nauda no Darbības | 1485.9 | 1307.11 | 2195.1 | 2430 | 2618.1 | 7081.3 |
| Nauda no Darbības | 104.7 | 145.467 | 148.2 | 210.3 | 235.9 | 286.2 |
| Deferred Taxes | -360.1 | 318.809 | -140 | -130.6 | 75.6 | -147.1 |
| Bezskaidras Naudas Preces | 605 | 570.858 | 439.5 | 435 | 297 | 783.4 |
| Cash Taxes Paid | 481.4 | 754.843 | 205.6 | 342.3 | 188.1 | 1218.4 |
| Samaksātie Procenti Naudā | 5.5 | 18.678 | 22.3 | 25 | 23.2 | 55.8 |
| Izmaiņas Apgrozāmajā Kapitālā | 240.8 | -926.533 | -697 | -200.5 | -1503.6 | -1916.5 |
| Nauda no Ieguldījumu Darbībām | -1046.8 | -1005.18 | -1463 | -2027.8 | -70.6 | -5384.7 |
| Kapitālie Izdevumi | -511.9 | -272.626 | -383.1 | -429.6 | -614.6 | -551.9 |
| Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | -534.9 | -732.556 | -1079.9 | -1598.2 | 544 | -4832.8 |
| Nauda no Darbībām ar Finansēšanu | -700.5 | -24.4 | -77.1 | -252.1 | -1970.5 | -1005.8 |
| Naudas Plūsma Finansēšanas Posteņos | -786.6 | -301.688 | -187.2 | -188 | -680.8 | -1032.7 |
| Akciju Izsniegšana (Atkāpšanās), Neto | 126.7 | 240.213 | 110.1 | -64.1 | -3271.6 | 26.9 |
| Parādu Izsniegšana (Atkāpšanās), Neto | -40.6 | 37.075 | 0 | 1981.9 | 0 | |
| Neto Izmaiņas Naudā | -261.4 | 277.53 | 655 | 150.1 | 577 | 690.8 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 1115.2 | 4214.1 | 5846.3 | 8075.3 | 973.5 |
| Cash From Operating Activities | 668.5 | 1295.2 | 4708.8 | 7081.3 | 2101.7 |
| Cash From Operating Activities | 67.4 | 138.5 | 211.7 | 286.2 | 74.3 |
| Deferred Taxes | 10.1 | 51.8 | 58.8 | -147.1 | -225 |
| Non-Cash Items | 15.2 | -84.9 | 153.1 | 783.4 | 455.7 |
| Changes in Working Capital | -539.4 | -3024.3 | -1561.1 | -1916.5 | 823.2 |
| Cash From Investing Activities | -1059 | -933.2 | -3372 | -5384.7 | -1705.3 |
| Capital Expenditures | -115.3 | -263.8 | -397 | -551.9 | -141.8 |
| Other Investing Cash Flow Items, Total | -943.7 | -669.4 | -2975 | -4832.8 | -1563.5 |
| Cash From Financing Activities | -366.4 | -484.6 | -99.2 | -1005.8 | 64.7 |
| Financing Cash Flow Items | -154.5 | -180.7 | -450.3 | -1032.7 | -98.8 |
| Issuance (Retirement) of Stock, Net | -211.9 | -303.9 | 351.1 | 26.9 | 163.5 |
| Net Change in Cash | -756.9 | -122.6 | 1237.6 | 690.8 | 461.1 |
| Issuance (Retirement) of Debt, Net | 0 | 0 | 0 |
| Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
|---|---|---|---|---|---|---|
| Fidelity Management & Research Company LLC | Investment Advisor | 9.7028 | 10390144 | 625604 | 2022-09-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.0279 | 8596620 | 75947 | 2022-09-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.9478 | 6369128 | -22691 | 2022-09-30 | LOW |
| Capital World Investors | Investment Advisor | 5.8138 | 6225599 | -9012 | 2022-09-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.7176 | 5051759 | -78876 | 2022-09-30 | LOW |
| JP Morgan Asset Management | Investment Advisor | 4.1569 | 4451385 | 73867 | 2022-09-30 | LOW |
| Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 2.2817 | 2443289 | 60342 | 2022-09-30 | LOW |
| Dodge & Cox | Investment Advisor/Hedge Fund | 2.1353 | 2286509 | 21175 | 2022-09-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 2.0919 | 2240113 | 26009 | 2022-09-30 | LOW |
| Capital International Investors | Investment Advisor | 1.6502 | 1767136 | -24799 | 2022-09-30 | LOW |
| Loomis, Sayles & Company, L.P. | Investment Advisor/Hedge Fund | 1.6031 | 1716617 | -48171 | 2022-09-30 | LOW |
| T. Rowe Price Associates, Inc. | Investment Advisor | 1.5049 | 1611534 | -82774 | 2022-09-30 | LOW |
| Invesco Capital Management (QQQ Trust) | Investment Advisor | 1.334 | 1428514 | -139196 | 2022-12-31 | LOW |
| Yancopoulos (George D) | Individual Investor | 1.1572 | 1239194 | -79973 | 2022-04-12 | LOW |
| American Century Investment Management, Inc. | Investment Advisor/Hedge Fund | 1.1001 | 1178071 | 1345 | 2022-09-30 | LOW |
| Putnam Investment Management, L.L.C. | Investment Advisor/Hedge Fund | 1.0308 | 1103833 | -7670 | 2022-09-30 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.9009 | 964691 | -15695 | 2021-12-31 | LOW |
| BlackRock Asset Management Ireland Limited | Investment Advisor | 0.8231 | 881403 | -1177 | 2022-09-30 | LOW |
| Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.8152 | 872985 | -10302 | 2022-09-30 | LOW |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7354 | 787491 | -15714 | 2022-09-30 | LOW |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group +485000+
Tirgotāji
65000+
Ikmēneša aktīvie klienti
$48000000+
Ikmēneša ieguldījumu apjoms
$28000000+
Izmēģināt tagad Izņemts katru mēnesi
Treidinga kalkulators
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Tirdzniecības komisija
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Finanšu svira
20:1
- 20
- 100
- 500
- 1000
- 10000
Investīcija
Darījuma apjoms (Kredītplecs x Investīcija):
Atvēršana
Aizvēršana
Īss Garšs
Regeneron Company profile
Par Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. ir integrēts biotehnoloģiju uzņēmums, kas atklāj, izgudro, izstrādā, ražo un komercializē zāles nopietnu slimību ārstēšanai. Uzņēmuma komercializētie medikamenti un izstrādes stadijā esošie produkti ir paredzēti, lai palīdzētu pacientiem ar acu slimībām, alerģiskām un iekaisuma slimībām, vēzi, sirds un asinsvadu un vielmaiņas slimībām, sāpēm, hematoloģiskām slimībām, infekcijas slimībām un retām slimībām. Uzņēmuma tirgū laistie produkti ir EYLEA (aflibercepts) injekcija, Dupixent (dupilumab) injekcija, Libtayo (cemiplimab) injekcija, Praluent (alirokumab) injekcija, REGEN-COV, Kevzara (sarilumab) šķīdums zemādas injekcijām, Evkeeza (evinakumaba) injekcija, Inmazeb (atoltivimaba, maftivimaba un odesivimaba-ebgn) injekcija, ARCALYST (rilonacepta) injekcija zemādas ievadīšanai un ZALTRAP (ziv-aflibercept) injekcija intravenozai infūzijai. Uzņēmuma klīniskajā izstrādē esošie kandidātprodukti cita starpā ir REGN4018, REGN5668 un Fasinumab.
| Industry: | Bio Therapeutic Drugs |
777 Old Saw Mill River Road
TARRYTOWN
NEW YORK 10591
US
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 485 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com